Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rio Tinto FY24 earnings fall short of estimates

(Sharecast News) - Mining giant Rio Tinto posted its weakest earnings in half a decade overnight, principally due to weaker iron ore prices. Rio Tinto said underlying earnings had dropped from $11.76bn in FY23 to $10.87bn in FY24, missing analysts' estimates, while EBITDA of $23.3bn also fell short of the $23.6bn consensus estimate. On a per share basis, earnings of $6.70 were short of expectations of $6.80 but Rio Tinto's final dividend of $2.25 per share was in line with expectations.

The FTSE 100-listed group did note that softer copper earnings as a result of weak demand out of China, were partly offset by a stronger performance by its aluminium wing and lower centralised costs. Underlying operating earnings for Rio Tinto's iron ore unit dropped 19% year-on-year, while its aluminium division reported a 61% year-on-year increase.

Net debt was also higher than predicted at $5.5bn as a result of increased capex and lower-than-expected contributions from its Simandou joint venture partner.

In a separate statement, Rio Tinto recommended shareholders vote against a resolution requesting a review of its dual-listed structure at its next annual general meeting in April.

"We are a global company, we have global investors, and London kind of works for us," said CEO Jakob Stausholm, who stated he doesn't believe that Rio would fundamentally change its value by swapping exchanges.

As of 0845 GMT, Rio Tinto shares were down 1.53% at 120.09p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.